FDA Deramiocel Duchenne Approval Blocked After HOPE-3 Data Findings
FDA Issues Complete Response Letter for Capricor’s Deramiocel BLA for Duchenne Muscular Dystrophy
For families affected by Duchenne muscular dystrophy, the FDA’s deramiocel decision means the evidence in Capricor Therapeutics’ application did not meet the standard for approval in the United States. On November 20, 2026, the agency issued a Complete Response Letter and a Regulatory Responsibility Letter following its review of the application and a Bioresearch Monitoring inspection.
The FDA said Study HOPE-3 failed to meet its prespecified primary and secondary efficacy endpoints. Its inspection also identified serious data integrity problems, including unauthorized post hoc changes to the statistical analysis plan, violations of blinding procedures, and additional protocol violations. The agency said the deficiencies could not be remedied after the fact.
CBER’s Office of Therapeutic Products issued the Complete Response Letter. The FDA also issued a Regulatory Responsibility Letter dated November 20 concerning observations from its inspection. A Complete Response Letter means the application was not approved as submitted. Capricor will have the opportunity to address the issues in the Regulatory Responsibility Letter.
Deramiocel is an allogeneic cardiosphere-derived cell therapy developed for people with Duchenne muscular dystrophy, a genetic disease that causes progressive muscle weakness. The application’s proposed use changed during the FDA review. Capricor initially sought treatment for cardiomyopathy associated with DMD, then proposed upper limb impairment after a July 29, 2026, advisory committee meeting.
The company also submitted 24-month open-label extension data from Study HOPE-3-OLE as a major amendment to its application. The FDA said it considered the additional data and the changed proposed indication, but the evidence still did not meet the standard for approval.
For patients and families, the decision means deramiocel has not received U.S. approval on the evidence reviewed. The FDA did not specify what additional evidence or steps would be needed for a future application, or when or whether Capricor will submit one.
Latest from Health
CDC: US Stroke Death Rates 2024 Show a 36.3% Drop Since 2000
Adults in their 30s and 40s may assume stroke is mainly an older person’s risk. But the US stroke death rates 2024 data shows increases among adults aged 35-44 during 2013-2024 and
NIH Ultra-Processed Food Research Targets Packaging Contaminants
NIH ultra-processed food research will examine more than nutrition For parents and grocery shoppers, the question is no longer only how much sugar or salt a packaged food contains. NIH’s new research
Medicare Advantage Food Benefits Face New ‘Healthy Food’ Standard Under 2028 CMS Rule
If you rely on Medicare Advantage for help with food, a regular doctor, or emergency care, a proposed federal rule could change what your plan covers in 2028. CMS wants plans to
NYC Mayor Zohran Mamdani Says Achilles Tear Requires Walking Boot
### STORY 10 — PRIORITY #10 Zohran Mamdani Achilles Tear: NYC Mayor Says He Will Wear a Boot New York City Mayor Zohran Mamdani said he tore his Achilles tendon during a
FDA Classifies Diversatek SafeGuide Guidewire Recall Class 2
The Diversatek SafeGuide guidewire recall covers two models that clinics and hospitals should check for: model 1214-02, lot 244736, and model 1214-02D, lots 245290 and 245321. The FDA classified both listings as
Glasgow hospital inquiry deaths linked to contaminated water
The families of patients who died at two Glasgow hospitals have spent years arguing that the buildings themselves were dangerous. At the Scottish Hospitals Inquiry, they finally heard the health board say
Kidsview Infant Bouncer Recall After 7 Collapses and 2 Infant Head Strikes
If you have a khaki Kidsview infant bouncer at home—or received one secondhand—stop using it and check the label on the back of the fabric seat. The U.S. Consumer Product Safety Commission
Daraxonrasib Trial Reports 13.2-Month Median Survival in Pancreatic Cancer
### STORY 1 — PRIORITY #1 Daraxonrasib Pancreatic Cancer Trial Reports 13.2-Month Median Survival For people with metastatic pancreatic cancer whose disease has progressed after earlier treatment, a once-daily pill is being
Endometriosis Genetic Study Findings: 27 New Regions and 314 Genes
Chronic pelvic pain and fertility challenges can lead people to seek answers about their symptoms. The endometriosis genetic study findings come from an NIH-supported analysis of more than 1 million participants. The
Next baby sleeping bag recall cites infant suffocation hazard
Parents across the UK should check their nurseries tonight. The Next baby sleeping bag recall issued this week covers a product designed to keep infants warm through the night, yet the item
Mycotoxins found in 212 tested plant-based foods, study reports levels below EU guidelines
People who eat plant-based burgers, sausages or milk alternatives may be concerned by a study finding fungal toxins in every product tested. Researchers examined 212 UK products and detected at least one
Daraxonrasib pancreatic cancer pill: FDA approval covers previously treated metastatic disease
Patients with advanced pancreatic cancer and their families may be asking whether daraxonrasib offers another treatment option after chemotherapy. The medicine, developed by Revolution Medicines and marketed as RASONQUE, is an oral
Sanniu Biscuits in California and 3 Other States Recalled Over Undeclared Milk and Shrimp
If you have a milk allergy and bought Sanniu biscuits in California, Illinois, Massachusetts, or New York, check the package before eating them. If you have a shrimp allergy, check Salt and
Alice Webb Inquest Hears Traces of Filler Found in Four Organs
The inquest into Alice Webb’s death heard that traces of cosmetic filler were found in her heart, lungs, brain and kidneys after a Brazilian butt-lift procedure. Webb was 33. The evidence reported
The Qpancy Pajama Recall: 1,309 Amazon Children’s Sets Pulled Over Burn Hazard — Refund Steps
If you bought Qpancy matching pajamas for a child and their doll on Amazon this year, check the labels and prints before your child wears them again. The U.S. Consumer Product Safety